tirzepatide addiction Emerging evidence continues to expand our understanding of GLP-1 receptor agonists beyond metabolic health. A recent study in adults with obesity who consumed alcohol found that patients receiving Semaglutide or reported Weight loss drugs and addiction:

However, a confirmatory post-approval study was stopped early due to safety concerns and a lack of clinical benefit

KFF estimates that GLP-1 prescriptions cost nearly $1,350 per employee, per month, while a proprietary projection model from pharmacy benefits optimizer RxBenefits found, that for an employer plan with 1,200 members, GLP-1 coverage could add between $73,000-$184,000 in plan ingredient costs in the first year

These findings mark a major advancement in expanding therapeutic options for individuals with obesity

This information helps clinicians distinguish between true autonomic dysfunction, medication side effects, and other causes

J Clin Endocrinol Metab (2020) 105(11):dgaa511

The American Diabetes Association reported weight reductions of 18% in one study and 20% in the other, along with better systolic blood pressure